The Weekly Summary

BMW-of-shooterMay 19th – May 26th

In the general news, the military in Thailand took control of the government. In the U.S., the House voted to limit NSA data collection. The poor quality of care by the VA system caused President Obama to comment, and he also made a surprise visit to the troops in Afghanistan. And yet again, another crazed lone gunman killed people, this time in California.

In healthcare business news, Medtronic (MDT) and Edwards (EW) resolved their legal disputes over TAVI patents. AstraZeneca (AZN) rebuffed Pfizer’s (PFE) bid to merge, and PFE walked away. Boston Scientific (BSX) acquired Bayer’s interventional unit, and Novartis (NVS) licensed the eye drug Fovista from Ophthotech (OPHT).

On the data front, Merck (MRK) and Endocyte (ECYT) withdrew their FDA application for ovarian cancer drug vintafolide after bad data. Also, Gilead’s (GILD) GS-5806, an oral pill to treat RSV, met endpoints.

From the FDA, Durata’s (DRTX) Dalvance was approved for skin infections. Also, Takeda’s Entyvio was approved for UC and Crohn’s.

In other regulatory news, the IRS put a stop to employers cutting healthcare insurance costs by dumping patients into Obamacare exchanges.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.